Literature DB >> 1755944

The role of C3 in the immune response.

A Erdei1, G Füst, J Gergely.   

Abstract

The complement system, particularly the third component, plays an important modulatory role in the inductive phase of the immune response. As discussed here by Anna Erdei and colleagues, the picture that is emerging is that immobilized C3 split products facilitate the cooperation between immunocompetent cells and are co-stimulatory molecules in T- and B-cell activation, probably as a result of their ability to promote cell-cell adhesion. In contrast, soluble C3 products inhibit lymphocyte proliferation.

Mesh:

Substances:

Year:  1991        PMID: 1755944     DOI: 10.1016/0167-5699(91)90011-H

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  27 in total

1.  A role for complement in the rejection of porcine ventral mesencephalic xenografts in a rat model of Parkinson's disease.

Authors:  R A Barker; E Ratcliffe; M McLaughlin; A Richards; S B Dunnett
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

2.  In situ localization of C3 synthesis in experimental acute renal allograft rejection.

Authors:  J R Pratt; K Abe; M Miyazaki; W Zhou; S H Sacks
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

3.  The effects of extracorporeal whole body hyperthermia on the functional and phenotypic features of canine peripheral blood mononuclear cells (PBMC).

Authors:  R J Kearns; S Ringler; S Krakowka; R Tallman; J Sites; M J Oglesbee
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

4.  Covalent binding of C3b to tetanus toxin: influence on uptake/internalization of antigen by antigen-specific and non-specific B cells.

Authors:  M B Villiers; C L Villiers; M R Jacquier-Sarlin; F M Gabert; A M Journet; M G Colomb
Journal:  Immunology       Date:  1996-11       Impact factor: 7.397

Review 5.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

6.  Anti-C1q receptor/calreticulin autoantibodies in patients with systemic lupus erythematosus (SLE).

Authors:  R H van den Berg; C E Siegert; M C Faber-Krol; T W Huizinga; L A van Es; M R Daha
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

7.  Molecular basis of immunity to rickettsial infection conferred through outer membrane protein B.

Authors:  Yvonne Gar-Yun Chan; Sean Phillip Riley; Emily Chen; Juan José Martinez
Journal:  Infect Immun       Date:  2011-03-28       Impact factor: 3.441

8.  Complement activation by malignant B cells from patients with chronic lymphocytic leukaemia (CLL).

Authors:  H V Marquart; K Grønbaek; B E Christensen; S E Svehag; R G Leslie
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

9.  Complement inhibition by human vitronectin involves non-heparin binding domains.

Authors:  M Sheehan; C A Morris; B A Pussell; J A Charlesworth
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

10.  Effects of decomplementation with cobra venom factor on experimental vasculitis.

Authors:  P W Mathieson; F J Qasim; S Thiru; R G Oldroyd; D B Oliveira
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.